EMA Confirms Marketing Authorization for BioMarin's Kuvan for Phenylketonuria Treatment
Regulatory Significance of EMA's Decision to Maintain Kuvan's Marketing Authorization
The European Medicines Agency (EMA) has confirmed the maintenance of the marketing authorization for Kuvan (sapropterin dihydrochloride), BioMarin Pharmaceutical's treatment for phenylketonuria (PKU). This Revision 23 report signifies that the drug's long-term safety and efficacy have been consistently demonstrated to the regulatory agency. Maintaining the marketing authorization after initial approval, through rigorous post-market monitoring, is a crucial factor in enhancing the drug's credibility in the European market. This is considered a result of BioMarin's efforts to minimize regulatory risks within the European Union and maintain a stable long-term supply chain.
Mechanism of Action of Sapropterin and its Role in PKU Treatment
Sapropterin, the active ingredient in Kuvan, is a synthetic derivative of tetrahydrobiopterin (BH4), a cofactor that assists in the activity of phenylalanine hydroxylase (PAH). The drug plays an essential role in promoting the metabolism of phenylalanine (Phe) in the body, preventing the accumulation of this toxic substance in the brain. In particular, a key therapeutic goal of this drug is to appropriately regulate blood phenylalanine levels to prevent cognitive impairment in pediatric patients. Given that there are limited pharmacological alternatives for patients with phenylketonuria, a rare genetic disease, the therapeutic value of Kuvan remains highly regarded.
Entry of Competing Drugs and BioMarin's Market Defense Strategy
The global PKU treatment market is currently estimated at approximately USD 1.18 billion in 2025 and is expected to continue to grow. However, with the expiration of Kuvan's substance patent, generic versions of the drug are being launched on the market, leading to price pressure and market share erosion. In response, BioMarin is implementing a portfolio transition strategy to accelerate the market launch of its follow-up enzyme replacement therapy, Palynziq (pegvaliase). Furthermore, despite the entry of strong competitors such as sepiapterin, developed by PTC Therapeutics, the continued maintenance of Kuvan's marketing authorization is expected to contribute to its continued role as a cash cow.
Historical Asset Acquisition Agreement and Long-Term Revenue Contribution Analysis
In October 2015, BioMarin entered into an agreement to acquire global rights (excluding Japan) to Kuvan and the then-under-development Palynziq from Merck Serono. This deal, with a total transaction value of USD 588.8 million, was a pivotal moment for BioMarin in strengthening its dominance in the rare disease area. Since the acquisition, Kuvan has provided a steady stream of revenue each year, serving as a reliable source of funding for the company's research and development (R&D) investments. This EMA decision to maintain the marketing authorization also demonstrates that the company's past large-scale investment assets continue to generate valid commercial value in the European market.
The confirmation of BioMarin's (BMRN) Kuvan marketing authorization signals that it will continue to serve as a stable cash cow in the global phenylketonuria (PKU) market, which is worth approximately USD 1.18 billion annually. In the short term, it is expected to protect against a sharp decline in sales by maintaining its credibility as an original drug in Europe in the face of aggressive penetration by generic products following the expiration of its substance patent. In the medium to long term, it provides sufficient regulatory buffer time to induce patient switching to the company's follow-up biosimilar, Palynziq, in response to the market entry of new competing drugs such as sepiapterin from PTC Therapeutics, which are in Phase 3 clinical trials. Furthermore, it suggests that BioMarin's strategic investment, which acquired global rights from Merck Serono for USD 588.8 million in 2015, continues to generate long-term value.
Source: EMA (ema)